About Prevail Partners
Prevail Partners is a venture capital firm founded in 2008. It is primarily based out of Philadelphia, United States. As of Jun 2024, Prevail Partners has invested in 5 companies. It primarily invests in Post IPO round in United States based startups. Its investments are spread across Life Sciences and Enterprise Applications sectors. Most recently it participated in the $***** Series A round of Triple Hair Overall, Prevail Partners portfolio has seen 2 IPOs, namely HemoGenyx and BriaCell Therapeutics. A lot of funds co-invest with Prevail Partners, with names like European Investment Bank sharing a substantial percentage of its portfolio. Prevail Partners has team of 12 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Post IPO, Series A & 1 more
Portfolio IPOs
Prevail Partners' List of All Investments
Prevail Partners has a portfolio of 5 companies. Their most notable investments are in SOM Biotech and PolyPhotonix.Their portfolio spans across United States, Canada, Spain and 1 more locations. They have invested in Life Sciences, Enterprise Applications, across Post IPO, Series A and 1 more. Here is the list of all investments by Prevail Partners:1. HemoGenyx
Developer of cell and gene therapies to treat blood diseases and viral infections. It offers apipeline of drug candidates which include HG‑CT‑1 CAR‑T therapy for relapsed or refractory acute myeloid leukemia, CDX Bi‑specific antibody to eliminate malignancy in patients with FLT3+ R/R AML and potentially condition bone marrow transplant, and Chimeric Bait Receptor Platform for antiviral and cancer immune cell reprogramming.
Key facts about HemoGenyx
- Founded Year: 2014
- Location: Buffalo (United States)
- Stage: Public
- Employee Count: 14 as on Dec 31, 2022
- Investors: Design Technologies, 43North and 3 Others
- Latest Funding Round: Post IPO, Feb 10, 2026, $*****
- Highlight: Public
Developer of immunotherapies for the treatment of cancer. Its lead product candidate, Bria-IMT is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. Bria-IMT is used in combination with multiple immune modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells. Another product Bria-OTS is shelf-personalized immunotherapy for the treatment of advanced-stage breast cancer.
Key facts about BriaCell Therapeutics
- Founded Year: 2004
- Location: Beverly Hills (United States)
- Stage: Public
- Employee Count: 22 as on Dec 03, 2025
- Investors: National Cancer Institute, ThinkEquity and 5 Others
- Latest Funding Round: Grant (prize money), Jan 08, 2025, $*****
- Highlight: Public
_1591251336620.png?format=webp&height=120&width=120){kind=logo}
3. SOM Biotech
SOM Biotech is developing therapies for rare diseases. The company has developed a proprietary ligand-based in-silico platform for virtual compound screening. The company has developed a drug pipeline that includes SOM0226 for the treatment of TTR amyloidosis (phase II) and SOM3355 for the treatment of Huntington's disease (phase II). The other products in the pipeline include compounds for the treatments for cystic fibrosis, glioblastoma, and Alzheimer's disease.
Key facts about SOM Biotech
- Founded Year: 2009
- Location: Barcelona (Spain)
- Stage: Series B
- Total Funding till date: $28.5M
- Employee Count: 22 as on Jul 01, 2024
- Investors: Additio Ventures, European Investment Bank and 3 Others
- Latest Funding Round: Series B, Dec 04, 2023, $*****
- Highlight: Editors' Pick
4. Triple Hair
Developer of treatments for alopecia. The products include Therapy-07 based on a combination of three molecules that prevents hair loss and stimulate regrowth of hair and also therapy-016 which has a proprietary natural active ingredient that promotes hair growth, thickness, and pigmentation.
Key facts about Triple Hair
- Founded Year: 2012
- Location: Dieppe (Canada)
- Stage: Series A
- Total Funding till date: $4M
- Employee Count: 8 as on Dec 31, 2024
- Investors: Invest Quebec, New Brunswick Innovation Foundation and 1 Other
- Latest Funding Round: Series A, Jun 03, 2024, $*****
5. PolyPhotonix
Developer of photonic technology-based devices to treat diabetic retinotherapy. The company develops non-invasive sleep masks that uses Organic Light-Emitting Devices (OLEDs), based on electroluminescence in certain organic molecules and polymers for the treatment for Diabetic Retinopathy and Diabetic Macular Oedema.
Key facts about PolyPhotonix
- Founded Year: 2008
- Location: Sedgefield (United Kingdom)
- Stage: Series A
- Total Funding till date: $10M
- Employee Count: 8 as on Mar 31, 2022
- Investors: Prevail Partners
- Latest Funding Round: Series A, Jan 20, 2022, $*****
- Highlight: Editors' Pick
Prevail Partners' Year-on-Year Investment Trends
Prevail Partners has invested in 5 companies over the last 4 years, with an average of 1 new investment annually in the last 3 years. Its most recent first time investment was in Triple Hair.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 1 | 0 | 1 |
2023 | 3 | 0 | 3 |
2022 | 1 | 0 | 1 |
Prevail Partners' Investments by Stage
Prevail Partners has made 2 investments in Post IPO stage with an average round size of $2.41M, 2 investments in Series A stage with an average round size of $7M and 1 investment in Series B stage with an average round size of $18.5M.Stage of entry | No. of Investments |
|---|---|
Post IPO | 2 |
Series A | 2 |
Series B | 1 |
Note: We have considered here, only first round of investments
Prevail Partners' Investments by Sector
Prevail Partners has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications and Sustainability Tech. Notably, it has invested in 5 Enterprise (B2B) companies, 5 Tech companies, 1 Saas company and at least 1 company focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 5 |
Enterprise Applications | 2 |
Sustainability Tech | 1 |
Note: We have considered here, only first round of investments
Prevail Partners' Investments by Geography
Prevail Partners has made most investments in United States (2), followed by Canada where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 2 |
Canada | 1 |
Spain | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
Prevail Partners' recent investments
Prevail Partners has not made any investment in 2026 so far.Here are the most recent investments by Prevail Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 03, 2024 | Canada | Series A | 1433 | ||
Dec 04, 2023 | Spain | Series B | 6632 | ||
Sep 18, 2023 | United States | Post IPO | 7989 | - | |
May 12, 2023 | United States | Post IPO | 4765 | - | |
Jan 20, 2022 | United Kingdom | Series A | 6452 | - |
IPOs and Publicly Listed companies in Prevail Partners' Portfolio
2 of Prevail Partners' portfolio companies have become public. HemoGenyx got listed on the London Stock Exchange (LSE), in Nov 2015 and BriaCell Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Prevail Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 09, 2015 | Sep 18, 2023 | Post IPO | 6777 | |
Nov 01, 2010 | May 12, 2023 | Post IPO | 8752 |
Team profile of Prevail Partners
Prevail Partners has a team of 12 members. Prevail Partners' team does not sit on the board of any company as of now.Co-investors of Prevail Partners
Over the past 4 years, 9 investors have co-invested in Prevail Partners's portfolio companies. This includes funds and angels.
- Invested before Prevail Partners: 43North, MINT Capital and 2 others have invested in rounds before Prevail Partners. There is 1 company where 43North has invested before Prevail Partners and 1 company where MINT Capital has invested before Prevail Partners.
- Top Co-investors of Prevail Partners: 3 investors entered a company along with Prevail Partners. These include investors like European Investment Bank (1 company).
- Invested after Prevail Partners: National Cancer Institute (1 company) and HHS (1 company) are the investors which have invested in Prevail Partners's portfolio after their investments.
Recent News related to Prevail Partners
•
Omnix Medical and Prevail Partners, LLC Announce Strategic and Financial PartnershipAccess Newswire•Nov 06, 2025•Prevail Partners, Omnix Medical, Prevail
•
•
Strategic Investment from Prevail Partners, LLCSatsuma Technology•Oct 02, 2024•Prevail Partners, HemoGenyx
•
•
•
•
PolyPhotonix Secures Multimillion Pound US Investment and Strategic Alliance for Sight Saving MaskMedical Device News•Jan 20, 2022•PolyPhotonix, Prevail Partners
